Showing results (121-130 of 682) with videos related to
Sort By:
Pageof 69
Expert Review of Hematology|August 12, 2017
Immunotherapy based approaches in myelofibrosisLucia Masarova, Srdan Verstovsek, Hagop Kantarjian, et al.Current Hematologic Malignancy Reports|April 29, 2010
Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasiaRuben A Mesa, Alfonso Quintás-Cardama, Srdan VerstovsekPharmacology & Therapeutics|April 29, 2014
Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insightsPrithviraj Bose, Yun Dai, Steven GrantExpert Opinion on Investigational Drugs|November 28, 2024
Investigational drugs in early phase trials for myelofibrosisSankalp Arora, Pankit Vachhani, Prithviraj BoseLeukemia & Lymphoma|February 1, 2017
Pathways and mechanisms of venetoclax resistancePrithviraj Bose, Varsha Gandhi, Marina KonoplevaClinical Lymphoma, Myeloma & Leukemia|February 10, 2024
SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic MyelofibrosisPankit Vachhani, Sanam Loghavi, Prithviraj BoseOncotarget|March 22, 2021
STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cellsUri Rozovski, David M Harris, Ping Li, et al.British Journal of Haematology|April 3, 2012
Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?Claire Harrison, Srdan Verstovsek, Mary F McMullin, et al.Clinical Lymphoma, Myeloma & Leukemia|December 18, 2014
Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasmsOlga Pozdnyakova, Robert P Hasserjian, Srdan Verstovsek, et al.British Journal of Haematology|March 6, 2019
SMAC mimetics as potential cancer therapeutics in myeloid malignanciesPrajwal Boddu, Bing Z Carter, Srdan Verstovsek, et al.Pageof 69